Shaanxi Panlong Pharmaceutical Group Co., Ltd. (SHE:002864)
China flag China · Delayed Price · Currency is CNY
21.05
+0.15 (0.72%)
Sep 30, 2026, 3:04 PM CST

SHE:002864 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
987.911,139971.45978.2971.04883.76
Other Revenue
1.521.882.412.633.263.73
989.421,141973.86980.83974.29887.48
Revenue Growth
-9.44%17.15%-0.71%0.67%9.78%32.40%
Cost of Revenue
447.25549.24381.74413.74408.25370.36
Gross Profit
542.17591.62592.12567.09566.04517.12
Selling, General & Admin
382.46416.56436.86418.79416.11386.15
Research & Development
43.0453.1137.5420.2618.2314.03
Other Operating Expenses
18.5811.169.3510.6110.239.29
Operating Expenses
461.5504.81485.59453.98452.94414.07
Operating Income
80.6786.81106.53113.11113.1103.05
Interest Expense
-1.77-2.18-1.56-6.11-13.92-3.49
Interest & Investment Income
4.1214.5525.5822.0617.1811.78
Other Non Operating Income (Expenses)
-0.92-0.58-0.220.312.55-5.27
EBT Excluding Unusual Items
82.198.6130.32129.37118.91106.06
Gain (Loss) on Sale of Investments
-0.13-0.13--1.56-0.11-
Gain (Loss) on Sale of Assets
-0.120.13-0.010.17--
Asset Writedown
-0.01-0.01-0.18-0.81-0.08-0
Other Unusual Items
15.2510.376.822.080.462.97
Pretax Income
97.09108.95136.95129.25119.18109.03
Income Tax Expense
18.7412.9317.0317.716.0314.47
Earnings From Continuing Operations
78.3596.02119.92111.55103.1594.56
Minority Interest in Earnings
0.170.260.35-1.11-1.98-1.39
Net Income
78.5296.28120.27110.43101.1693.17
Net Income to Common
78.5296.28120.27110.43101.1693.17
Net Income Growth
-34.98%-19.95%8.91%9.16%8.58%17.77%
Shares Outstanding (Basic)
136136136125111111
Shares Outstanding (Diluted)
136136136127112111
Shares Change
-0.16%0.06%7.01%13.03%1.16%-0.60%
EPS (Basic)
0.580.710.880.880.910.84
EPS (Diluted)
0.580.710.880.870.900.84
EPS Growth
-34.87%-20.00%1.77%-3.42%7.33%18.48%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
147.8520.674.5441.5369.5335.36
Free Cash Flow Per Share
1.090.150.550.330.620.32
Dividend Per Share
0.2920.2690.1920.1690.1540.139
Dividend Growth
8.58%39.99%13.65%10.01%11.05%20.02%
Gross Margin
54.80%51.86%60.80%57.82%58.10%58.27%
Operating Margin
8.15%7.61%10.94%11.53%11.61%11.61%
Profit Margin
7.94%8.44%12.35%11.26%10.38%10.50%
Free Cash Flow Margin
14.94%1.81%7.65%4.23%7.14%3.98%
EBITDA
119.29123.15139.04142.92130.16117.8
EBITDA Margin
12.06%10.79%14.28%14.57%13.36%13.27%
D&A For EBITDA
38.6236.3432.5129.8117.0714.74
EBIT
80.6786.81106.53113.11113.1103.05
EBIT Margin
8.15%7.61%10.94%11.53%11.61%11.61%
Effective Tax Rate
19.30%11.87%12.43%13.70%13.45%13.27%
Revenue as Reported
989.421,141973.86980.83974.29887.48
Advertising Expenses
-1.35.041.091.763.68